FDA says marijuana has a legitimate medicinal purpose

Original Article ↗ Hacker News Discussion ↗

Mounting evidence and a new FDA stance that marijuana has legitimate medical uses are intensifying calls to legalize or at least reschedule cannabis under U.S. federal law. Commenters contrast its therapeutic benefits—especially for insomnia, pain, and anxiety—with risks like dependency, poor sleep quality, cannabinoid hyperemesis, and cognitive effects, emphasizing the need for moderation and better clinical research. The exchange broadens into critiques of the drug scheduling framework, comparisons with alcohol, tobacco and opioids, and concerns that politics and enforcement priorities, rather than science, have long driven U.S. drug policy.

Medical and Symptomatic Uses (Especially Sleep and Pain)

  • Many report cannabis, especially edibles, as highly effective for insomnia, RLS, neuropathic pain, jet lag, anxiety, and general “racing mind” at bedtime.
  • Users describe dosing patterns (e.g., 20mg THC with CBN, indica-leaning products, THC+CBD flower) and costs ($150/month) as acceptable relative to the benefit of decent sleep.
  • Some find THC lets them “turn off thoughts” and even normalize sleep long-term after stopping. Others report improved dream experience and trauma-related sleep issues.
  • Comparisons with prescription meds (trazodone, quetiapine, benzos, z-drugs, antihistamines) highlight trade-offs: side effects, dependence, and less natural-feeling sleep.

Tolerance, Side Effects, and Risks

  • Tolerance buildup is common; some cycle between cannabis and prescription meds to reset.
  • Reported downsides: next-day cognitive fog, disrupted REM, poor sleep quality despite easier sleep onset, racing thoughts, anxiety, “the fear” (paranoia/agoraphobia), dependence concerns, nausea/CHS, reflux, and withdrawal-like sleep issues on stopping.
  • Multiple counter-anecdotes: cannabis worsens insomnia or does nothing short of very high doses.

Strains, Cannabinoids, and Dosing Nuance

  • Perceived differences between indica vs sativa, THC percentage, and cannabinoid/terpene “entourage” profiles.
  • Several note benefit from CBD and CBN combinations; high-CBD hemp mixed with THC is one strategy.
  • Emphasis that optimal dose and composition are highly individual and often require experimentation.

Legal Status, Scheduling, and Policy

  • Strong support for broad legalization and treating cannabis like other legal plants (kava, kratom, salvia), or like alcohol/tobacco.
  • Debate over U.S. scheduling: many see Schedule I status for cannabis, LSD, and psilocybin as absurd given emerging medical evidence; some expect rescheduling to Schedule III at most.
  • Discussion of harm-based vs “medical use”–based scheduling; calls for consistent inclusion of alcohol/tobacco.
  • Concerns that prohibition has stifled rigorous per-condition clinical trials and left users reliant on anecdotes.

Skepticism About the Reported FDA Shift

  • Some participants question whether the cited “FDA says…” claim is based on a new, official report, suggesting it may be misreporting or rehash of older HHS/DEA correspondence.